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Abstract Bovine pancreatic trypsin inhibitor (BPTI) is an
important model for the study of protein folding. Herein we
describe a robust approach to the total chemical synthesis of
BPTI using native chemical ligation of unprotected peptide
segments in aqueous solution. After refolding and oxidative
formation of disulfides, the target protein was purified by affinity
chromatography. The synthetic BPTI was characterized by mass
spectrometry, inhibition assay, thermal denaturation and 2D
NMR spectroscopy, and was shown to be structurally and
functionally identical to natural BPTI. The synthetic strategy
presented in this paper has enabled us to establish rapid access to
novel analogues of BPTI.
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1. Introduction
Bovine pancreatic trypsin inhibitor (BPTI) is a protein con-
sisting of 58 amino acid residues with three disul¢de bridges,
and is arguably the most extensively studied small protein
molecule. Studies on BPTI have covered almost all aspects
of modern protein research, including: protein folding and
stability; protein-protein recognition; protein (re)design; X-
ray crystallography, and nuclear magnetic resonance (NMR)
spectroscopy; calculation and molecular dynamics; biosynthe-
sis and evolution; and, therapeutic treatment of diseases [1].
Not surprisingly, a strong interest in obtaining natural and/or
unnatural analogues of BPTI has for years continued una-
bated, and the BPTI model system has stimulated methodo-
logical advances in protein production, from enzymatic and
chemical semisynthesis to recombinant DNA-based expression
technologies.
Semisynthesis [1], and particularly recombinant DNA-based
expression [2,3], has played a dominant role in producing
large quantities of BPTI analogues. Despite obvious potential
advantages, total chemical synthesis has remained a rarely
used approach to obtaining analogues of the protein. Even
though several heroic total chemical syntheses of BPTI were
reported in the 1970s [4^6], the homogeneity of some of these
synthetic products would probably be called into question
using today’s standards for protein characterization. Recently,
a successful synthesis of BPTI and two disul¢de-lacking ana-
logues using stepwise Fmoc SPPS was reported [7]. The syn-
thetic wild type BPTI was found to be indistinguishable from
the naturally occurring inhibitor by all criteria applied. The
desire to understand the fundamentals of the BPTI model
protein system means that total chemical synthesis and the
systematic variation of covalent structure will play a more
prominent role in the future.
In the past decade, solid phase peptide chemistry has wit-
nessed tremendous technological advances in both synthesis
[8,9] and analytical techniques [10]. Despite this progress,
stepwise assembly of large polypeptide (s 50 amino acid res-
idues) still remains a challenging task due to the geometric
increase in the numbers of resin-bound side products accumu-
lated during a stepwise solid phase synthesis. This limitation
of the size of synthetic polypeptide chains has been overcome
by recently developed chemoselective ligation strategies [11],
in particular, the powerful native chemical ligation technique
[12]. The chemical ligation of unprotected peptide segments in
aqueous solution is a robust and practical method for making
synthetic polypeptide chains up to more than 100 amino acid
residues [13]. Syntheses of a number of proteins of moderate
size by a rapid single-step native chemical ligation have been
reported, including interleukin-8 [12] and barnase [14], Abl
SH3 [15], turkey ovomucoid third domain [16,17], human se-
cretory phospholipase A2 [18] and a number of chemokines
[19,20].
In this paper we describe the total chemical synthesis of
wild type BPTI using native chemical ligation, in an e¡ort
to establish rapid and robust synthetic access to an expanded
repertoire of analogues of the BPTI protein molecule.
2. Materials and methods
2.1. Materials
Boc-L-amino acids and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyl-
uroniumhexa£uorophosphate (HBTU) were purchased from Nova-
biochem; Boc-Ala-OCH2-Pam-resin and N,N-diisopropylethylamine
(DIEA) were obtained from Applied Biosystems. Aminomethyl-resin
was prepared by Dr. Michael Carrasco according to published proce-
dures [21]. Acetonitrile was purchased from Fisher Scienti¢c, tri-
£uoroacetic acid (TFA) from Halocarbon Products Co., and HF
from Matheson Gas Products. Bromoacetic acid and thiophenol
were purchased from Aldrich Chemical Co. Bovine K-chymotrypsin,
L-trypsin and natural BPTI puri¢ed from bovine pancreas were pur-
chased from Worthington Biochemical Co. All chromogenic sub-
strates used in inhibitory activity assays were obtained from Bachem
Bioscience Inc. Anhydrotrypsin was prepared according to [22] and
was coupled to CNBr-activated Sepharose 4B (Pharmacia) according
to the coupling procedures provided by the manufacturer.
Analytical reversed phase HPLC was performed on a Hewlett Pack-
ard Series 1050, using a Vydac C-18 column (5 Wm, 4.6U150 mm);
preparative reversed phase HPLC was carried out on a Waters Delta
Prep 4000 system using a Vydac C-18 column (15^20 Wm, 50U250
mm); solvent A for HPLC was water containing 0.1% TFA; solvent B
was 90% acetonitrile containing 0.1% TFA. Mass spectrometry anal-
ysis was carried out on a PE Sciex API-III quadrupole electrospray
ionization mass spectrometer (ESI-MS). The inhibitor-enzyme associ-
ation equilibrium constants were measured on a Hewlett-Packard
FEBS 20312 8-6-98
0014-5793/98/$19.00 ß 1998 Federation of European Biochemical Societies. All rights reserved.
PII S 0 0 1 4 - 5 7 9 3 ( 9 8 ) 0 0 5 4 7 - X
*Corresponding author. Fax: (1) (650) 952-3055.
E-mail: wuyuan_lu@gryphonsci.com
FEBS 20312 FEBS Letters 429 (1998) 31^35
HP8450A spectrophotometer by a modi¢ed version of the Green and
Work method [23,24]. The experiment was carried out at 21 þ 1‡C at
pH 8.3 in 0.1 M Tris-HCl bu¡er containing 0.02 M CaCl2 and 0.005%
Triton X-100. Thermal denaturation was performed on a Calorimetry
Sciences Nano-DSC microcalorimeter at pH 3.0. 1H NMR spectra
were acquired on a Bruker AMX500 spectrometer at 27‡C, pH 5.3.
The principles of native chemical ligation, in which two unprotected
peptide segments form a native peptide bond by forming an inter-
mediate thioester ligation product followed by a spontaneous SCN
acyl rearrangement, have been described [12,14]. The experimental
procedures brie£y outlined below were largely adopted from the syn-
thesis of turkey ovomucoid third domain, another serine proteinase
inhibitor of similar size [16,17]. The design of the synthetic strategy is
illustrated in Fig. 1.
2.2. Synthesis of BPTI(1^37)KCOSH
The thioacid peptide was manually synthesized on Boc-Gly-(thio-
ester linker)-aminomethyl-resin [25], using the optimized in situ neu-
tralization/HBTU activation protocol for Boc chemistry [9]. After the
chain assembly was complete, the peptide was deprotected and
cleaved by HF in the presence of 5% p-cresol at 0‡C for 1 h. To
obtain the corresponding thioester peptide needed in the ligation re-
action, the crude thioacid peptide BPTI(1^37)KCOSH was allowed to
react with bromoacetic acid for 30 min (1 mg/ml bromoacetic acid,
5 mg/ml peptide, in 0.1 M NaOAc, 6 M GuHCl, pH 4.0). The
thioester product (1^37)KCOS-CH2COOH was subsequently puri¢ed
by preparative C18 reversed phase HPLC using a gradient of 30^50%
B (yield 15%). The molecular weight of the thioester peptide was
ascertained by ESI-MS (observed 4289.9 þ 0.5 Da; calculated 4290.9
Da, average isotope composition).
2.3. Synthesis of BPTI(38^58)
The C-terminal peptide segment was manually synthesized on Boc-
Ala-OCH2-Pam-resin using the same chain assembly chemistry as
described above. After deprotection and cleavage in HF, the crude
peptide was puri¢ed by preparative C18 reversed phase HPLC run-
ning a gradient of 15^30% B (yield 25%). The molecular weight of the
peptide was found to be 2318.3 þ 0.6 Da, which was in good agree-
ment with the calculated value 2318.7 Da (average isotope composi-
tion).
2.4. Native chemical ligation
BPTI(1^37)KCOS- CH2COOH (56 mg, 13.1 Wmol) and BPTI(38^
58) (32 mg, 13.8 Wmol) were dissolved in 8.8 ml of 0.1 M phosphate
bu¡er, pH 7.5, containing 6 M GuHCl and 3% thiophenol. As shown
in Fig. 2, the ligation reaction essentially went to completion in 24 h
(most of the starting materials were actually converted to the product
within 8 h). The ligated full-length BPTI polypeptide was puri¢ed by
preparative C18 reversed phase HPLC (30^50%B) (yield 60%). The
molecular weight of the ligation product, 6517.4 þ 0.6 Da, was in good
accord to the calculated value of 6517.6 Da (average isotope compo-
sition). It is interesting to point out that there was a brief accumu-
lation of intermediates (marked as peaks a, b, and c in Fig. 2) in the
early stage of the ligation reaction. Further analysis by ESI-MS re-
vealed that peaks a and b were probably two di¡erent cyclized thio-
ester intermediate forms of (1^37)KCOS-CH2COOH, and peak c was
thiophenol ester peptide (1^37)KCOS-Ph.
2.5. Folding and puri¢cation
Protein folding was carried out by dissolving 52 mg (8.0 Wmol) of
reduced BPTI(1^58) at 1.2 mg/ml in 0.6 M Tris-HCl, 6 mM EDTA,
6 M GuHCl, pH 8.7, which was then diluted 6-fold with water. The
folding solution was gently stirred in an open air container at room
temperature overnight, and then was loaded onto an anhydrotrypsin-
Sepharose a⁄nity column. After washes with unbu¡ered salt solution,
the bound fractions were eluted by lowering the pH to 2. The active
protein collected from the a⁄nity column was further puri¢ed by
cation ion exchange SP-Sepharose chromatography at pH 4.8, fol-
lowed by desalting and lyophilization (yield 45%).
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Fig. 1. Strategy for the synthesis of BPTI by native chemical liga-
tion.
Fig. 2. Native chemical ligation of BPTI(1^37)KCOSR and
BPTI(38^58). The ligation reaction was monitored by analytical C-
18 RP-HPLC (0^67% B over 24 min) and ESI-MS. Peaks a, b and
c represent reaction intermediates (for details see Section 2).
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3. Results and discussion
3.1. Scale and yields
Peptide syntheses were carried out on 0.4 mmol of Boc-Ala-
Pam resin and of Boc-Gly-(thioester linker)-aminomethyl res-
in. Yields of puri¢ed peptides were 25% for BPTI(38^58) (100
Wmol) and 15% for BPTI(1^37)KCOS-CH2COOH (60 Wmol),
respectively. Native chemical ligation was carried out on a 13
Wmol scale, yielding 52 mg of full-length BPTI(1^58) (60%).
Refolding and subsequent puri¢cation gave rise to 23 mg of
active BPTI (45%). The overall yield of the synthesis was 4%,
so that more than 100 mg of synthetic protein can be obtained
from reaction and work-up of the two synthetic peptide seg-
ments.
The success of any synthesis, to a large extent, is dictated by
the quality of the product. For this reason, we carefully char-
acterized the synthetic BPTI.
3.2. Electrospray mass spectrometry
The synthetic product before and after folding was analyzed
by ESI-MS (Fig. 3). The mass for the folded BPTI was found
to be 6511.3 þ 0.7 Da (calculated 6511.6 Da, average isotope
composition), whereas the molecular weight of the unfolded
form was determined to be 6517.4 þ 0.6 Da (calculated 6517.6
Da, average isotope composition). The di¡erence in the ob-
served masses (6 units) for the oxidized and reduced BPTI
indicate that three disul¢de bridges, as expected, have formed
during refolding. To demonstrate that the synthetic protein
folded correctly, however, additional functional and structural
characterizations were conducted as described below.
3.3. Inhibitory activity assay
BPTI is a strong inhibitor of bovine L-trypsin. Our syn-
thetic BPTI inhibited bovine L-trypsin stoichiometrically
(data not shown), indicating that it is a strong inhibitor of
trypsin. Even though an estimated association equilibrium
constant (Ka) of about 1014 M31 has often been cited in the
literature [1], few groups have actually been able to accurately
measure a binding constant that high [26]. This is because the
dissociation rate constant (koff) for BPTI-trypsin complex is so
low that an impractical amount of time will be needed in
order for the system to reach equilibrium. For that reason,
accurate measurement of the Ka value with trypsin was not
attempted. Instead, Ka values for the synthetic BPTI and nat-
urally occurring BPTI interacting with chymotrypsin were de-
termined (Fig. 4). They are 8.4U107 M31 and 7.7U107 M31,
respectively, which are in good agreement with the values
reported in the literature [1]. These results suggest that the
synthetic BPTI is indeed functionally identical to the natural
inhibitor.
FEBS 20312 8-6-98
Fig. 3. ESI-MS analysis of BPTI before and after folding. The observed mass after folding is 6 Da lower than that of the fully reduced BPTI,
as expected for the formation of three disul¢des.
Fig. 4. Inhibition of bovine K-chymotrypsin by synthetic and natu-
ral BPTI.
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3.4. Thermal denaturation
BPTI is one of the most stable small proteins ever reported
[27]. To demonstrate the structural integrity of the synthetic
BPTI, thermal denaturation was performed for both synthetic
BPTI and natural BPTI on a di¡erential scanning microca-
lorimeter at pH 3.0. As shown in Fig. 5, the two proteins have
almost identical melting transition and melting temperatures,
which strongly suggested that the synthetic BPTI was cor-
rectly folded.
3.5. 1H NMR
In order to evaluate the three-dimensional structure of
BPTI synthesized in this manner, 2D COSY, TOCSY, and
NOESY spectra were acquired using standard methods. The
spectra were entirely consistent with data reported previously
for natural BPTI [28]. A portion of the TOCSY spectrum is
shown in Fig. 6. This and other NMR data con¢rmed that the
synthetic material was folded correctly, i.e. in the same con-
formation as native BPTI.
4. Conclusions
We have described a practical and robust synthetic access to
BPTI by straightforward native chemical ligation, which al-
lows for facile production of previously unobtainable ana-
logues of this intensively studied model protein. In fact, using
the synthetic strategy outlined in this paper, we have made
and studied the properties of some novel topological ana-
logues of the BPTI molecule (unpublished results). One ob-
vious advantage of native chemical ligation is the ease with
which a large number of analogues can be produced. Given
the tremendous need for novel analogues of BPTI for the
study of protein folding, protein stability, protein-protein rec-
ognition, and protein de novo design, etc., the establishment
of robust synthetic access to BPTI is a timely development.
Using the convenient total chemical synthesis described here,
novel analogues not accessible by conventional (i.e. recombi-
nant DNA-based) means in both side chains and the back-
bone of the BPTI protein molecule can be readily prepared.
These analogues will provide the foundation for systematic
dissection of the molecular basis of important aspects of the
BPTI system, and will lead to improved understanding of
protein structure/function relationships
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